Reports
Sale
Dementia Drugs Market Size, Trends, Analysis, Forecast: By Indication Type: Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications; By Treatment; By Dosage; By Route of Administration; By Distribution Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Dementia Drugs Market Outlook
The dementia drugs market size in the 7 major markets was valued at USD 16.6 billion in 2023, driven by the increasing prevalence of dementia. The market is expected to grow at a CAGR of 8.2% during the forecast period of 2024-2032, with the values likely to rise from USD 17.9 billion in 2024 to USD 33.8 billion by 2032.
Dementia Drugs Market Overview
Dementia drugs are used to treat symptoms of dementia by increasing the levels of acetylcholine, a neurotransmitter involved in learning and memory. They aim at improving the quality of the patient’s life for individuals affected by the disease.
Alzheimer’s dementia affects approximately 6.7 million Americans aged 65 years or older. The number is expected to reach around 13.8 million by 2060. The generation lying between an age span of 65 to 74 years is at the highest risk of developing Alzheimer’s dementia. Women are more vulnerable to develop dementia and account for two-third of the cases. The prevalence of Alzheimer dementia is expected to witness a surge in low- and middle-income countries by 68%. As a result, the dementia drugs market demand is projected to experience a significant rise in coming years.
Growth in FDA Approvals
With a better understanding of the disease pathophysiology, the scientists have made notable breakthroughs by offering new and improved categories of dementia drugs. There is ongoing research on dementia drugs that primarily focuses on addressing the complex nature of the disease. In January 2023, the U.S. Food and Drug Administration approved Eisai’s Leqembi (lecanemab-irmb) for treating Alzheimer’s disease by reducing amyloid beta plaque, a notable marker of the disease. The results were based on the results of a Phase 3 trial that confirmed the clinical benefits of the drug.
The dementia drugs market growth is further aided with rising research activities, conducted by prominent healthcare companies. In May 2023, Eli Lilly revealed that their latest Alzheimer drug Donanemab helped in slowing the disease progression by 35% along with a slowed decline over 18 months. The results were announced as per the TRAILBLAZER ALZ 2 Phase 3 study. The reduced progression may be considered as a major help to improve patient longevity.
Surge in Investment in Aid Enhanced Research
The rising investments in research and development activities is a major factor for boosting the dementia drugs market value. In November 2023, PREDICTOM secured a USD 26.7 million investment to develop an artificial intelligence screening platform that identifies the risk of dementia development in patients, even before the onset of symptoms. The company aims to reduce the strain of healthcare services and related expenditure with the help of digital biomarkers.
In November 2023, the Alzheimer’s Associations made a USD 100 million investment for drug development research activities. The investment spans across 53 countries and 6 continents and contains approximately 1000 active research projects, aimed at developing improved therapeutic drugs. Such initiatives are expected to foster market growth as well.
Dementia Drugs Market Segmentation
Market Breakup by Indication Type
- Lewy Body Dementia
- Parkinson’s Disease Dementia
- Alzheimer’s Disease
- Vascular Dementia
- Other Indications
Market Breakup by Treatment
- Cholinesterase Inhibitors
- NMDA Antagonists and its Combination Drugs
- Others
Market Breakup by Dosage
- Injection
- Tablets
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Dementia Drugs Market Regional Analysis
The United States is a major market for dementia drugs as the region has a high disease prevalence. The presence of key pharmaceutical players along with notable research centers play a critical role in boosting the dementia drugs market growth in the region.
Europe is a leading market with a high emphasis on providing relevant information on diagnosing early signs of the disease to facilitate better treatment options. Having a robust healthcare infrastructure that integrates all the latest technologies in the drug development process is another major contributor to the market value. In October 2023, AstronauTx , a biotechnology company received a USD 61 million investment to develop new treatment for Alzheimer’s disease. The company is currently in collaboration with UK UCL Drug Discovery Institute (UCL DDI) to develop medications that resets astrocyte behavior (important support cells in the brain).
In the forecast period, the Asia Pacific region is expected to witness a notable boost in the dementia drugs market share. This can be attributed to growing investments to improve the healthcare and research framework pertaining to the region.
Dementia Drugs Market: Competitor Landscape
In December 2023, Bristol Myers Squibb acquired Karuna Therapeutics with a USD 12.7 billion deal. Karuna Therapeutics’ KarXT is a potential first in class treatment for Alzheimer’s disease psychosis. The deal aligns with Bristol Myers Squibb’s vision to expand their neuroscience portfolio and provide effective solutions by developing and commercialising medicines on a global scale and help patients battling with fatal neural diseases.
The key features of the dementia drugs market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Abbvie Inc
- Apotex inc.
- Eisai
- Aurobindo Pharma Ltd
- Novartis AG
- F. Hoffmann-La Roche AG
- Eli Lilly and Company
- Johnson & Johnson
- Teva Pharmaceutical Industries
- Biogen
- Annovis Bio
- Merck & Co.
- GlaxoSmithKline PLC
- Athira Pharma
- AstraZeneca
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication Type |
|
| Breakup by Treatment |
|
| Breakup by Dosage |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Dementia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Dementia Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Dementia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Dementia Epidemiology Forecast (2017-2032)
5.3.1 Germany Dementia Epidemiology Forecast (2017-2032)
5.3.2 France Dementia Epidemiology Forecast (2017-2032)
5.3.3 Italy Dementia Epidemiology Forecast (2017-2032)
5.3.4 Spain Dementia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Dementia Epidemiology Forecast (2017-2032)
5.4 Japan Dementia Epidemiology Forecast (2017-2032)
6 Dementia Drugs Market Overview – Seven Major Markets
6.1 Dementia Drugs Market Historical Value (2017-2023)
6.2 Dementia Drugs Market Forecast Value (2024-2032))
7 Dementia Drugs Market Landscape- Seven Major Markets
7.1 Dementia Drugs Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Dementia Drugs Product Landscape
7.2.1 Analysis by Diseases Type
7.2.2 Analysis by Treatments
7.2.3 Analysis by Route of Administration
8 Dementia Drugs Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Dementia Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Dementia Drugs Market Segmentation - Seven Major Markets
11.1 Dementia Drugs Market by Indication Type
11.1.1 Market Overview
11.1.2 Lewy Body Dementia
11.1.3 Parkinsons Disease Dementia
11.1.4 Alzheimers Disease
11.1.5 Vascular Dementia
11.1.6 Other Indications
11.2 Dementia Drugs Market by Treatment
11.2.1 Market Overview
11.2.2 Cholinesterase Inhibitors
11.2.3 NMDA Antagonists and its Combination Drugs
11.2.4 Others
11.3 Dementia Drugs Market by Dosage
11.3.1 Market Overview
11.3.2 Injection
11.3.3 Tablets
11.3.4 Others
11.4 Dementia Drugs Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Others
11.5 Dementia Drugs Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.6 Dementia Drugs Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Dementia Drugs Market
12.1 Dementia Drugs Market Historical Value (2017-2023)
12.2 Dementia Drugs Market Forecast Value (2024-2032)
12.3 Dementia Drugs Market by Disease Type
12.4 Dementia Drugs Market by Treatment Type
13 EU-4 and United Kingdom Dementia Drugs Market
13.1 Dementia Drugs Market Historical Value (2017-2023)
13.2 Dementia Drugs Market Forecast Value (2024-2032)
13.3 Germany Dementia Drugs Market Overview
13.3.1 Dementia Drugs Market by Disease Type
13.3.2 Dementia Drugs Market by Treatment Type
13.4 France Dementia Drugs Market Overview
13.4.1 Dementia Drugs Market by Disease Type
13.4.2 Dementia Drugs Market by Treatment Type
13.5 Italy Dementia Drugs Market Overview
13.5.1 Dementia Drugs Market by Disease Type
13.5.2 Dementia Drugs Market by Treatment Type
13.6 Spain Dementia Drugs Market Overview
13.6.1 Dementia Drugs Market by Disease Type
13.6.2 Dementia Drugs Market by Treatment Type
13.7 United Kingdom Dementia Drugs Market Overview
13.7.1 Dementia Drugs Market by Disease Type
13.7.2 Dementia Drugs Market by Treatment Type
14 Japan Dementia Drugs Market
14.1 Dementia Drugs Market Historical Value (2017-2023)
14.2 Dementia Drugs Market Forecast Value (2024-2032)
14.2.1 Dementia Drugs Market by Disease Type
14.2.2 Dementia Drugs Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Abbvie Inc
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Apotex inc.
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Eisai
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Aurobindo Pharma Ltd
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Novartis AG
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 F. Hoffmann-La Roche AG
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Eli Lilly and Company
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Johnson & Johnson
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Teva Pharmaceutical Industries
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Biogen
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Annovis Bio
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Merck & Co.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 GlaxoSmithKline PLC
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Athira Pharma
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 AstraZeneca
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Dementia Drugs Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 16.6 billion in 2023, driven by the rising prevalence of dementia across the globe.
The market is anticipated to grow at a CAGR of 8.2% during the forecast period of 2024-2032, likely to reach a market value of USD 33.8 billion by 2032.
The market demand is driven by the increasing incidence of the Alzheimer, along with rising advancements in drug development.
The current market trend involves increasing number of drug approvals by the regulatory authorities such as the FDA. In January 2023, Eisai’s Leqembi (lecanemab-irmb) gained FDA approval for treating Alzheimer’s disease by reducing amyloid beta plaque, a critical marker of the disease.
It includes Lewy Body dementia, Parkinsons disease dementia, Alzheimer’s disease, and vascular dementia, among others.
Cholinesterase inhibitors, NMDA antagonists along with its combination drugs, among others are common treatments available in the market.
Based on dosage types, the market is divided into injection and tablets, among others.
Major distribution channels include hospital pharmacies and retail pharmacies, among others.
The route of administration can be oral, parenteral, and others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the market.
Key players involved in the market are Abbvie Inc., Apotex inc., Eisai, Aurobindo Pharma Ltd., Novartis AG, F. Hoffmann-La Roche AG, Eli Lilly and Company, Johnson & Johnson, Teva Pharmaceutical Industries, Biogen, Annovis Bio, Merck & Co., GlaxoSmithKline PLC, Athira Pharma, and AstraZeneca.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER